Federal Register / Vol. 87, No. 48 / Friday, March 11, 2022 / Notices 14021 

ACTION: Notice. 

SUMMARY: Findings of research 

misconduct have been made against 

Terry Magnuson, Ph.D. (Respondent), 

Kay M. & Van L. Weatherspoon Eminent 

Distinguished Professor, Department of 

Genetics, School of Medicine (SOM), 

University of North Carolina at Chapel 

Hill (UNC). Respondent engaged in 

research misconduct in research 

included in one (1) grant application for 

U.S. Public Health Service (PHS) funds, 

specifically National Cancer Institute 

(NCI), National Institutes of Health 

(NIH), grant application R01 CA267946– 

01A1. The administrative actions, 

including supervision from February 25, 

2022–January 5, 2024, are detailed 

below. 

FOR FURTHER INFORMATION CONTACT: 

Wanda K. Jones, Dr.P.H., Acting 

Director, Office of Research Integrity, 

1101 Wootton Parkway, Suite 240, 

Rockville, MD 20852, (240) 453–8200. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the Office of Research 

Integrity (ORI) has taken final action in 

the following case: 

Terry Magnuson, Ph.D., University of 

North Carolina at Chapel Hill: Based on 

the report of an assessment conducted 

by UNC, Respondent’s admission, and 

additional analysis conducted by ORI in 

its oversight review, ORI found that Dr. 

Terry Magnuson, Kay M. & Van L. 

Weatherspoon Eminent Distinguished 

Professor, Department of Genetics, 

SOM, UNC, engaged in research 

misconduct in research included in one 

(1) grant application for PHS funds, 

specifically NCI, NIH, grant application 

R01 CA267946–01A1. 

ORI found that Respondent engaged 

in research misconduct by intentionally, 

knowingly, or recklessly plagiarizing 

text from the following three (3) online 

articles and one (1) published paper: 

• Comprehensive Guide to 

Understanding and Using CUT&Tag 

Assay. November 4, 2020. https://

www.activemotif.com/blog-cut-tag 

(hereafter referred as ‘‘Blog cut&tag 

2020’’). 

• Complete Guide to Understanding 

and Using ATAC-Seq. February 9, 2021. 

https://www.activemotif.com/blog-atacseq (hereafter referred as ‘‘Blog ATACSeq 2021’’). 

• Illumina CATCH–IT. https://

www.illumina.com/science/sequencingmethod-explorer/kits-and-arrays/catchit.html (hereafter referred as ‘‘Illumina 

Catch-it’’). 

• Modeling Physiological Events in 

2D vs. 3D Cell Culture. Physiology 

(Bethesda) 2017 Jul;32(4):266–277; doi: 

10.1152/physiol.00036.2016 (hereafter 

referred as ‘‘Physiology (Bethesda) 

2017’’). 

Plagiarized text was included in: 

• Grant application R01 CA267946– 

01A1, ‘‘Genome-wide dynamics of 

chromatin modifiers,’’ submitted to 

NCI, NIH, on March 1, 2021 (hereafter 

referred as ‘‘R01 CA267946–01A1’’) 

Specifically, ORI found that 

Respondent knowingly, intentionally, or 

recklessly plagiarized from: 

• The introduction (p. 266) and 

techniques (p. 267) sections of 

Physiology (Bethesda) 2017 to 

compose subsection ‘‘ii. Identifying 

changes to SWI/SNF composition 

driven by cell state changes’’ of 

Specific Aim 1 of R01 CA267946– 

01A1 

• the introduction and sections ‘‘What 

is CUT&Tag’’ and ‘‘Before CUT&Tag, 

There Was CUT&RUN’’ of Blog 

cut&tag 2020 to compose the ‘‘CHIPseq protocols’’ description in R01 

CA267946–01A1 

• the ‘‘What is ATAC-Seq?’’ section of 

Blog ATAC-Seq 2021 to compose the 

‘‘ATAC-seq protocols’’ description in 

R01 CA267946–01A1 

• the web page ‘‘Illumina Catch-it’’ 

describing the CATCH–IT technology 

to compose the ‘‘Pitfalls & 

Alternatives’’ section of Specific Aim 

1 in R01 CA267946–01A1 

Dr. Magnuson entered into a 

Voluntary Settlement Agreement 

(Agreement) and voluntarily agreed to 

the following: 

(1) Respondent will have his research 

supervised from February 25, 2022– 

January 5, 2024 (the ‘‘Supervision 

Period’’). Prior to the submission of an 

application for PHS support for a 

research project on which Respondent’s 

participation is proposed and prior to 

Respondent’s participation in any 

capacity in PHS-supported research, 

Respondent will submit a plan for 

supervision of Respondent’s duties to 

ORI for approval. The supervision plan 

must be designed to ensure the integrity 

of Respondent’s research. Respondent 

will not participate in any PHSsupported research until such a 

supervision plan is approved by ORI. 

Respondent will comply with the 

agreed-upon supervision plan. 

(2) The requirements for Respondent’s 

supervision plan are as follows: 

i. The respondent will submit his 

grant applications seeking PHS support 

to the Vice Dean, UNC SOM, thirty (30) 

days prior to the grant application 

submission deadline. The SOM Office of 

Research (OR) will review Respondent’s 

grant applications to check for 

plagiarism and ensure compliance with 

acceptable scientific practice for citation 

of prior work. SOM OR will not recruit 

Respondent’s supervisor or 

collaborators to review his grant 

applications. SOM OR will submit a 

report to ORI at six (6) month intervals 

setting forth the committee meeting 

dates and Respondent’s compliance 

with appropriate research standards and 

confirming the integrity of Respondent’s 

research. 

ii. SOM OR will conduct an advance 

review of any report, manuscript, or 

abstract involving PHS-supported 

research in which Respondent is 

involved. The review will include a 

discussion with Respondent of the 

primary data represented in those 

documents and will include a 

certification to ORI that the data 

presented and the text in the report, 

manuscript, or abstract is supported by 

the research record and not plagiarized. 

(3) During the Supervision Period, 

Respondent will ensure that any 

institution employing him submits, in 

conjunction with each application for 

PHS funds, or report, manuscript, or 

abstract involving PHS-supported 

research in which Respondent is 

involved, a certification to ORI that the 

data provided by Respondent are based 

on actual experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are 

accurately reported and not plagiarized 

in the application, report, manuscript, 

or abstract. 

(4) If no supervision plan is provided 

to ORI, Respondent will provide 

certification to ORI at the conclusion of 

the Supervision Period that his 

participation was not proposed on a 

research project for which an 

application for PHS support was 

submitted and that he has not 

participated in any capacity in PHSsupported research. 

Dated: March 8, 2022. 

Wanda K. Jones, 

Acting Director, Office of Research Integrity, 

Office of the Assistant Secretary for Health. 

[FR Doc. 2022–05217 Filed 3–10–22; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Impact of Health Misinformation in the 

Digital Information Environment in the 

United States Throughout the COVID– 

19 Pandemic Request for Information 

(RFI); Correction 

AGENCY: Office of the Surgeon General, 

Department of Health and Human 

Services. 

ACTION: Notice; correction. 


lotter on DSK11XQN23PROD with NOTICES1
14022 Federal Register / Vol. 87, No. 48 / Friday, March 11, 2022 / Notices 

SUMMARY: The Office of the Surgeon 

General published a document in the 

Federal Register of March 7, 2022, 

requesting information regarding the 

Impact of Health Information 

Misinformation in the Digital 

Information Environment in the United 

States Throughout the COVID–19 

Pandemic. The document included a 

hyperlink in which the public will not 

be able to access. 

FOR FURTHER INFORMATION CONTACT: Max 

Lesko at COVIDMisinfoRFI@hhs.gov or 

at (202) 893–5020. 

SUPPLEMENTARY INFORMATION: 

Correction 

In the Federal Register of March 7, 

2022, in FR Doc. 2022–04777, on page 

12713, in the third column, correct the 

section which reads, ‘‘a. Starting with, 

but not limited to, these common 

examples of COVID–19 vaccine 

misinformation documented by the 

Centers for Disease Control and 

Prevention (CDC), any aggregate data 

and analysis on the prevalence of 

COVID–19 misinformation on 

individual platforms including exactly 

how many users saw or may have been 

exposed to instances of COVID–19 

misinformation.’’ to read, ‘‘a. Starting 

with but not limited to https://

www.cdc.gov/coronavirus/2019-ncov/ 

vaccines/facts.html of COVID–19 

vaccine misinformation documented by 

the Centers for Disease Control and 

Prevention (CDC), any aggregate data 

and analysis on the prevalence of 

COVID–19 misinformation on 

individual platforms including exactly 

how many users saw or may have been 

exposed to instances of COVID–19 

misinformation.’’ 

Max Lesko, 

Chief of Staff, Office of the Surgeon General. 

[FR Doc. 2022–05132 Filed 3–10–22; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; American Women: 

Assessing Risk Epidemiologically (AWARE) 

(R01 Clinical Trial Optional). 

Date: April 5, 2022. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G22B, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Kristina S. Wickham, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G22B, 

Rockville, MD 20852, 301–761–5390, 

kristina.wickham@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: March 7, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–05136 Filed 3–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK Data 

Coordinating Center. 

Date: April 5, 2022. 

Time: 12:30 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health/NIDDK, 

6707 Democracy Blvd., Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Elena Sanovich, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7351, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, 301–594–8886, 

sanoviche@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: March 7, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–05135 Filed 3–10–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development and 

Commercialization of Fusion Proteins 

for the Treatment of Growth Disorders 

and Diseases of Cartilage 

Degeneration 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development and the National 

Cancer Institute, both institutes of the 

National Institutes of Health, 

Department of Health and Human 

Services, are contemplating the grant of 

an Exclusive Patent License to practice 

the inventions embodied in the Patents 

and Patent Applications listed in the 

Supplementary Information section of 

this Notice to Cavalry Biosciences, Inc. 

of San Francisco, CA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before March 28, 2022 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Richard T. Girards, Jr., Esq., 

MBA, Senior Technology Transfer 

Manager, National Institutes of Health, 


lotter on DSK11XQN23PROD with NOTICES1